It is administered as a once-weekly subcutaneous injection following a structured dose-escalation schedule, typically starting at 2 mg and increasing to 812 mg weekly in Phase 2 protocols
By targeting three different receptors, retatrutide may reduce appetite, lead to significant fat loss, and all while brilliantly maintaining metabolism
We need to treat it like one, just like we treat hypertension or high cholesterol. Two GLP-1 agonists and one dual GIP/GLP-1 agonist are currently FDA-approved to treat obesity
After Steady State (Weekly Use) With weekly injections, the drug accumulates to steady state over ~45 weeks
By systematically examining this wide array of disorders, the study sheds light on the potential therapeutic roles of GLP-1RAs beyond their established metabolic applications
Compare your specific prescribed medication cost